Cure My Disease

Don't miss your cure!

 Log in / Sign up

Swiss study reveals Real-World impact of MS drug kesimpta

NCT ID NCT05285904

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 107 adults in Switzerland with relapsing multiple sclerosis who were already taking Kesimpta (ofatumumab) as part of their routine care. Researchers tracked how many patients had no signs of disease activity, including relapses, new brain lesions, or worsening disability. The goal was to see how well the drug works outside of a controlled clinical trial setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

  • Novartis Investigative Site

    Baden, Canton of Aargau, 5405, Switzerland

  • Novartis Investigative Site

    Lucerne, Canton of Lucerne, 6004, Switzerland

  • Novartis Investigative Site

    Lucerne, Canton of Lucerne, 6006, Switzerland

  • Novartis Investigative Site

    Sargans, Canton of St. Gallen, 7320, Switzerland

  • Novartis Investigative Site

    Gland, Canton of Vaud, 1196, Switzerland

  • Novartis Investigative Site

    Zurich, Canton of Zurich, 8006, Switzerland

  • Novartis Investigative Site

    Zurich, CHE, 8001, Switzerland

  • Novartis Investigative Site

    Basel, 4001, Switzerland

  • Novartis Investigative Site

    Bern, 3010, Switzerland

  • Novartis Investigative Site

    Lausanne, 1011, Switzerland

  • Novartis Investigative Site

    Lucerne, 6000, Switzerland

  • Novartis Investigative Site

    Lugano, 6900, Switzerland

  • Novartis Investigative Site

    Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.